Associations Between Genetically Predicted Plasma N-Glycans and Prostate Cancer Risk: Analysis of Over 140,000 European Descendants

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Litwin MS, Tan H-J. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532–2542. doi:10.1001/jama.2017.7248
   PubMed Web of Science ®Google Scholar
• Pezaro C, Woo HH, Davis ID. Prostate cancer: measuring PSA. Intern Med J. 2014;44(5):433–440. doi:10.1111/imj.12407
   PubMed Web of Science ®Google Scholar
• Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA. 2005;294(1):66–70. doi:10.1001/jama.294.1.66
   PubMed Web of Science ®Google Scholar
• Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level≤ 4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–2246. doi:10.1056/NEJMoa031918
   PubMed Web of Science ®Google Scholar
• Parekh DJ, Ankerst DP, Troyer D, Srivastava S, Thompson IM. Biomarkers for prostate cancer detection. J Urol. 2007;178:2252–2259. doi:10.1016/j.juro.2007.08.055
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–2035. doi:10.1016/S0140-6736(14)60525-0
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–1328. doi:10.1056/NEJMoa0810084
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–1319. doi:10.1056/NEJMoa0810696
   PubMed Web of Science ®Google Scholar
• Munkley J. The glycosylation landscape of pancreatic cancer. Oncol Lett. 2019;17:2569–2575.
   PubMed Web of Science ®Google Scholar
• Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540–555. doi:10.1038/nrc3982
   PubMed Web of Science ®Google Scholar
• Demetriou M, Nabi IR, Coppolino M, Dedhar S, Dennis JW. Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V. J Cell Biol. 1995;130(2):383–392. doi:10.1083/jcb.130.2.383
   PubMed Web of Science ®Google Scholar
• Seberger PJ, Chaney WG. Control of metastasis by Asn-linked, β1–6 branched oligosaccharides in mouse mammary cancer cells. Glycobiology. 1999;9:235–241. doi:10.1093/glycob/9.3.235
   Web of Science ®Google Scholar
• Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med. 2000;6:306–312. doi:10.1038/73163
   PubMed Web of Science ®Google Scholar
• Takahashi M, Kuroki Y, Ohtsubo K, Taniguchi N. Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. Carbohydr Res. 2009;344:1387–1390. doi:10.1016/j.carres.2009.04.031
   PubMed Web of Science ®Google Scholar
• Yoshimura M, Nishikawa A, Ihara Y, Taniguchi S, Taniguchi N. Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Proc Natl Acad Sci. 1995;92:8754–8758. doi:10.1073/pnas.92.19.8754
   PubMed Web of Science ®Google Scholar
• Zhao Y, Sato Y, Isaji T, et al. Branched N‐glycans regulate the biological functions of integrins and cadherins. FEBS J. 2008;275:1939–1948. doi:10.1111/j.1742-4658.2008.06346.x
   PubMed Web of Science ®Google Scholar
• Scott E, Munkley J. Glycans as biomarkers in prostate cancer. Int J Mol Sci. 2019;20(6):1389. doi:10.3390/ijms20061389
   Web of Science ®Google Scholar
• Stanley P, Schachter H, Taniguchi N. N-Glycans. In: Varki A, Cummings RD, Esko JD, et al, eds. Essentials of Glycobiology. 2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2009. Chapter 8.
   Google Scholar
• Lange T, Ullrich S, Müller I, et al. Human prostate cancer in a clinically relevant xenograft mouse model: identification of β (1, 6)-branched oligosaccharides as a marker of tumor progression. Clin Cancer Res. 2012;18(5):13641373. doi:10.1158/1078-0432.CCR-11-2900
   Web of Science ®Google Scholar
• Doherty M, Theodoratou E, Walsh I, et al. Plasma N-glycans in colorectal cancer risk. Sci Rep. 2018;8:1–12. doi:10.1038/s41598-018-26805-7
   Web of Science ®Google Scholar
• Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133–1163. doi:10.1002/sim.3034
   PubMed Web of Science ®Google Scholar
• Teumer A. Common methods for performing Mendelian randomization. Front Cardiovasc Med. 2018;5:51. doi:10.3389/fcvm.2018.00051
   Web of Science ®Google Scholar
• Swerdlow DI, Kuchenbaecker KB, Shah S, et al. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. Int J Epidemiol. 2016;45(5):1600–1616. doi:10.1093/ije/dyw088
   PubMed Web of Science ®Google Scholar
• Sharapov SZ, Tsepilov YA, Klaric L, et al. Defining the genetic control of human blood plasma N-glycome using genome-wide association study. Hum Mol Genet. 2019;28:2062–2077.
   PubMed Web of Science ®Google Scholar
• Klarić L, Tsepilov YA, Stanton CM, et al. Glycosylation of immunoglobulin G is regulated by a large network of genes pleiotropic with inflammatory diseases. Sci Advan. 2020;6:eaax0301. doi:10.1126/sciadv.aax0301
   Web of Science ®Google Scholar
• Benedetti E, Pučić-Baković M, Keser T, et al. Network inference from glycoproteomics data reveals new reactions in the IgG glycosylation pathway. Nat Commun. 2017;8:1483. doi:10.1038/s41467-017-01525-0
   Web of Science ®Google Scholar
• Akmačić IT, Ugrina I, Štambuk J, et al. High-throughput glycomics: optimization of sample preparation. Biochemistry. 2015;80(7):934–942. doi:10.1134/S0006297915070123
   Web of Science ®Google Scholar
• Lauc G, Huffman JE, Pučić M, et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet. 2013;9(1):e1003225. doi:10.1371/journal.pgen.1003225
   PubMed Web of Science ®Google Scholar
• Wu L, Wang J, Cai Q, et al. Identification of novel susceptibility loci and genes for prostate cancer risk: a transcriptome-wide association study in over 140,000 European descendants. Cancer Res. 2019;79(13):3192–3204. doi:10.1158/0008-5472.CAN-18-3536
   Web of Science ®Google Scholar
• Schumacher FR, Al Olama AA, Berndt SI, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50(7):928. doi:10.1038/s41588-018-0142-8
   Web of Science ®Google Scholar
• Wu L, Yang Y, Guo X, et al. An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. Nat Commun. 2020;11(1):3905. doi:10.1038/s41467-020-17673-9
   Web of Science ®Google Scholar
• Hartwig FP, Davies NM, Hemani G, Davey Smith G. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol. 2016;45(6):1717–1726. doi:10.1093/ije/dyx028
   PubMed Web of Science ®Google Scholar
• Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408. doi:10.7554/eLife.34408
   PubMed Web of Science ®Google Scholar
• Wu L, Shu X, Bao J, et al. PRACTICAL, CRUK, BPC3, CAPS, PEGASUS Consortia. Analysis of over 140,000 European descendants identifies genetically predicted blood protein biomarkers associated with prostate cancer risk. Cancer Res. 2019;79(18):4592–4598. doi:10.1158/0008-5472.CAN-18-3997
   Web of Science ®Google Scholar
• Zhu J, Shu X, Guo X, et al. Associations between genetically predicted blood protein biomarkers and pancreatic cancer risk. Cancer Epidemiol Prev Biomarkers. 2020;29(7):1501–1508. doi:10.1158/1055-9965.EPI-20-0091
   Web of Science ®Google Scholar
• Brion M-JA, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013;42(5):1497–1501. doi:10.1093/ije/dyt179
   PubMed Web of Science ®Google Scholar
• Bause E, Breuer W, Schweden J, Roeser R, Geyer R. Effect of substrate structure on the activity of Man9-mannosidase from pig liver involved in N-linked oligosaccharide processing. Eur J Biochem. 1992;208(2):451–457. doi:10.1111/j.1432-1033.1992.tb17207.x
   Google Scholar
• Clerc F, Reiding KR, Jansen BC, Kammeijer GS, Bondt A, Wuhrer M. Human plasma protein N-glycosylation. Glycoconj J. 2016;33:309–343.
   PubMed Web of Science ®Google Scholar
• Novokmet M, Lukić E, Vučković F, et al. Changes in IgG and total plasma protein glycomes in acute systemic inflammation. Sci Rep. 2014;4(1):4347. doi:10.1038/srep04347
   PubMed Web of Science ®Google Scholar
• Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353(9165):1649–1652. doi:10.1016/S0140-6736(99)01046-6
   PubMed Web of Science ®Google Scholar
• Kawahara R, Ortega F, Rosa-Fernandes L, et al. Distinct urinary glycoprotein signatures in prostate cancer patients. Oncotarget. 2018;9(69):33077. doi:10.18632/oncotarget.26005
   Google Scholar
• Bhat G, Hothpet V-R, Lin M-F, Cheng P-W. Shifted Golgi targeting of glycosyltransferases and α-mannosidase IA from giantin to GM130-GRASP65 results in formation of high mannose N-glycans in aggressive prostate cancer cells. Biochimica et Biophysica Acta. 2017;1861(11):2891–2901. doi:10.1016/j.bbagen.2017.08.006
   Web of Science ®Google Scholar
• Saldova R, Fan Y, Fitzpatrick JM, Watson RWG, Rudd PM. Core fucosylation and α2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 2011;21(2):195–205. doi:10.1093/glycob/cwq147
   PubMed Web of Science ®Google Scholar
• Murphy K, Murphy BT, Boyce S, et al. Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer. Mol Oncol. 2018;12(9):1513–1525. doi:10.1002/1878-0261.12348
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Hatakeyama S, Yoneyama T, et al. Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer. Sci Rep. 2019;9:1–8. doi:10.1038/s41598-019-53384-y
   Web of Science ®Google Scholar
• Ishibashi Y, Tobisawa Y, Hatakeyama S, et al. Serum tri- and tetra-antennary N -glycan is a potential predictive biomarker for castration-resistant prostate cancer. Prostate. 2014;74(15):1521–1529. doi:10.1002/pros.22869
   PubMed Web of Science ®Google Scholar
• Wang D. N-glycan cryptic antigens as active immunological targets in prostate cancer patients. J Proteomics Bioinform. 2012;5(04):090. doi:10.4172/jpb.1000218
   Google Scholar
• Ishikawa T, Yoneyama T, Tobisawa Y, et al. An automated micro-total immunoassay system for measuring cancer-associated α2, 3-linked sialyl N-glycan-carrying prostate-specific antigen may improve the accuracy of prostate cancer diagnosis. Int J Mol Sci. 2017;18(2):470. doi:10.3390/ijms18020470
   PubMed Web of Science ®Google Scholar
• Llop E, Ferrer-Batallé M, Barrabés S, et al. Improvement of prostate cancer diagnosis by detecting PSA glycosylation-specific changes. Theranostics. 2016;6(8):1190. doi:10.7150/thno.15226
   PubMed Web of Science ®Google Scholar
• Munkley J, Mills IG, Elliott DJ. The role of glycans in the development and progression of prostate cancer. Nat Rev Urol. 2016;13(6):324. doi:10.1038/nrurol.2016.65
   PubMed Web of Science ®Google Scholar
• Wang D, Herzenberg LA, Peehl DM, Herzenberg LA Prostate cancer glycan markers and autoantibody signatures. Google Patents. 2011.
   Google Scholar
• Wang D, Dafik L, Nolley R, et al. Anti-oligomannose antibodies as potential serum biomarkers of aggressive prostate cancer. Drug Dev Res. 2013;74(2):65–80. doi:10.1002/ddr.21063
   Web of Science ®Google Scholar
• Lorenzo GD, Zappavigna S, Crocetto F, et al. Assessment of total, PTEN -, and AR-V7 + circulating tumor cell count by flow cytometry in patients with metastatic castration-resistant prostate cancer receiving enzalutamide. Clin Genitourin Cancer. 2021. doi:10.1016/j.clgc.2021.03.021
   Web of Science ®Google Scholar
• Ferro M, Lucarelli G, Crocetto F, et al. First-line systemic therapy for metastatic castration-sensitive prostate cancer: an updated systematic review with novel findings. Crit Rev Oncol Hematol. 2021;157:103198. doi:10.1016/j.critrevonc.2020.103198
   PubMed Web of Science ®Google Scholar
• Buonerba C, Ferro M, Dolce P, et al. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;151:102992. doi:10.1016/j.critrevonc.2020.102992
   Web of Science ®Google Scholar
• Bruzzese D, Mazzarella C, Ferro M, et al. Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with “gray” prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. Transl Res. 2014;164(6):444–451. doi:10.1016/j.trsl.2014.06.006
   Web of Science ®Google Scholar